Events Calendar

Mon
Tue
Wed
Thu
Fri
Sat
Sun
M
T
W
T
F
S
S
27
28
29
30
31
1
2
12:00 AM - NextGen UGM 2025
3
4
6
7
8
9
10
11
12
13
14
15
16
17
10:00 AM - MEDICA 2025
18
19
20
21
22
23
24
25
26
27
28
29
30
NextGen UGM 2025
2025-11-02 - 2025-11-05    
12:00 am
NextGen UGM 2025 is set to take place in Nashville, TN, from November 2 to 5 at the Gaylord Opryland Resort & Convention Center. This [...]
Preparing Healthcare Systems for Cyber Threats
2025-11-05    
2:00 pm
Healthcare is facing an unprecedented level of cyber risk. With cyberattacks on the rise, health systems must prepare for the reality of potential breaches. In [...]
MEDICA 2025
2025-11-17 - 2025-11-20    
10:00 am - 5:00 pm
Expert Exchange in Medicine at MEDICA – Shaping the Future of Healthcare MEDICA unites the key players driving innovation in medicine. Whether you're involved in [...]
Events on 2025-11-02
NextGen UGM 2025
2 Nov 25
TN
Events on 2025-11-05
Events on 2025-11-17
MEDICA 2025
17 Nov 25
40474 Düsseldorf

Events

Latest News

Neuropathic Pain Market growing at a 5.5 % of CAGR by 2023

MRFR Press Release/- Market Research Future had published a half-cooked research report on global neuropathic pain market.

Market Highlights

Neuropathic pain is a complex and chronic pain that usually occurs due to tissue damage. During this state nerve fibers damage themselves and this damage to nerves sends incorrect signals to pain centers. Increasing number of diabetic and cancer patients together are the major driving factor for this market’s growth.  Beside this increasing approval of novel treatment for neuropathic pain, increasing number of pain management centers and increasing demand for generic drugs has provided a fuel for the growth of this market. On the other hand increasing cost of branded drugs and increasing side effects of the steroid therapy can restrain the growth of this market.

Global neuropathic pain market is expected to grow at the CAGR of 5.5% during forecasted period.

Based on regions global neuropathic pain market is segmented into North America, Europe, Asia Pacific plus Middle East and Africa. North America and Europe has share in more than half of the global neuropathic pain market. Due to the well-developed medical and pharmaceutical sector, government supports research and development. Along with this increasing prevalence of disease which causes neuropathic pain especially diabetic and cancer is the major driving factor for neuropathic pain market in North America and Europe. Asia Pacific has given opportunities for developing neuropathic pain market here due to increasing demand of drugs for neuropathic pain and increasing prevalence of disease like diabetes.

Report Details @ https://www.marketresearchfuture.com/reports/neuropathic-pain-market

Segmentation:

This market is segmented into by drug types (anticonvulsants, antidepressant, anaesthesia, steroids and other), by condition (Peripheral Neuropathy, Diabetic Neuropathy and other) and by end user (retail pharmacies, hospitals and other)

On the basis of application it is segmented into peripheral neuropathy, diabetic neuropathy and others. On the basis of end users the market is segmented into retail pharmacies, hospitals and others.

There are many key players in the global neuropathic pain market. Some of them are Pfizer Inc., Depomed Inc., Johnson & Johnson Services Inc., Eli Lily and Company, GlaxoSmithKline PLC, Bristol-Myers Squibb and Company, Sanofi S.A, Baxter Healthcare Corporation and Biogen Idec Inc.

Due to increasing prevalence of neuropathic pain globally many companies are in the race to introduce better oral treatment for neuropathic pain. Companies are using a trend of strategic alliance and acquisition to gain the market and minimize competition in the market.

Pfizer is one of the leading pharmaceutical companies of the world. They have introduced LYRICA (pregabalin) for management of neuropathic pain associated with spinal cord injury which is approved by FDA.  Earlier this drug was used for the treatment of neuropathic pain associated with diabetes. They have also introduce PainDETECT which is a simple screening tool developed to detect neuropathic pain (NeP) components in patients suffering from low back pain.

Depomed Inc. a pharmaceutical company focuses  on products to treat pain and CNS condition, this company  has introduced  Lazanda® (fentanyl) nasal spray CII for the management of pain in cancer patients and Zipsor® (diclofenac potassium) liquid filled capsules for relief of mild to moderate or acute pain.

Eli Lily and Company has introduced CYMBALTA® (duloxetine HCl) which is FDA approved antidepressant for the treatment of pain caused due to diabetic peripheral neuropathy.

GlaxoSmithKline a UK based pharmaceutical company has submitted results of phase II clinical trial for Horizant™ which manages  neuropathic pain associated with post-herpetic neuralgia.  They are performing clinical trials for NCT00969059 to be used for the treatment of   neuropathic pain patients with peripheral nerve injury.

Biogen Idec Inc. has introduces CNV1014802 (raxatrigine) use for the treatment of neuropathic pain.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Akash Anand,

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: akash.anand@marketresearchfuture.com